# A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

> **NCT05358717** · PHASE2 · COMPLETED · sponsor: **PTC Therapeutics** · enrollment: 159 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** PTC518
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05358717
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-03
- **Primary completion:** 2025-02-07
- **Final completion:** 2025-07-31
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05358717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05358717, "A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05358717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*